Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease

Next Previous
Trial Profile

Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPK 3006 (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms RESOLUTE
  • Sponsors Spark Therapeutics

Most Recent Events

  • 30 Oct 2023 Time frame changed from 52 weeks to Up to 5 years.
  • 30 Oct 2023 Planned End Date changed from 1 Oct 2027 to 1 Apr 2032.
  • 30 Oct 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Apr 2032.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top